281 related articles for article (PubMed ID: 25465810)
1. Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation.
Konishi A; Shinke T; Otake H; Nishio R; Sawada T; Takaya T; Nakagawa M; Osue T; Taniguchi Y; Iwasaki M; Kinutani H; Masaru K; Takahashi H; Terashita D; Shite J; Hirata K
Int J Cardiol; 2015 Jan; 179():476-83. PubMed ID: 25465810
[TBL] [Abstract][Full Text] [Related]
2. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
[TBL] [Abstract][Full Text] [Related]
3. Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Park J; Shin DH; Kim BK; Her AY; Kim YH; Choi HH; Kim JS; Ko YG; Choi D; Jang Y; Hong MK
Eur Heart J Cardiovasc Imaging; 2013 Dec; 14(12):1181-6. PubMed ID: 23657678
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel.
Nishio R; Shinke T; Otake H; Sawada T; Haraguchi Y; Shinohara M; Toh R; Ishida T; Nakagawa M; Nagoshi R; Kozuki A; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Shite J; Hirata K
Circ J; 2012; 76(10):2348-55. PubMed ID: 22785462
[TBL] [Abstract][Full Text] [Related]
5. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).
Kim JS; Kim BK; Jang IK; Shin DH; Ko YG; Choi D; Hong MK; Cho YK; Nam CW; Hur SH; Choi JH; Song YB; Hahn JY; Choi SH; Gwon HC; Jang Y
Am Heart J; 2012 Apr; 163(4):601-7. PubMed ID: 22520526
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K
Circ J; 2011; 75(1):99-105. PubMed ID: 21099121
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel.
Li S; Shi Y; Wang H; Zhang W; Liu J
J Thromb Thrombolysis; 2015 Jul; 40(1):88-96. PubMed ID: 25800884
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
9. Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis.
Konishi A; Shinke T; Otake H; Takaya T; Osue T; Kinutani H; Kuroda M; Takahashi H; Terashita D; Hirata K
J Cardiol; 2016 Jun; 67(6):531-7. PubMed ID: 26299610
[TBL] [Abstract][Full Text] [Related]
10. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
[TBL] [Abstract][Full Text] [Related]
11. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Ichikawa M; Takei Y; Hamasaki T; Kijima Y
Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
[TBL] [Abstract][Full Text] [Related]
12. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of detailed arterial healing response at seven months following implantation of an everolimus- or sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction.
Sawada T; Shinke T; Otake H; Mizoguchi T; Iwasaki M; Emoto T; Terashita D; Mizuguchi T; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
Int J Cardiol; 2013 Sep; 168(2):960-6. PubMed ID: 23164597
[TBL] [Abstract][Full Text] [Related]
15. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
Räber L; Magro M; Stefanini GG; Kalesan B; van Domburg RT; Onuma Y; Wenaweser P; Daemen J; Meier B; Jüni P; Serruys PW; Windecker S
Circulation; 2012 Mar; 125(9):1110-21. PubMed ID: 22302840
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
17. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.
Adriaenssens T; Dens J; Ughi G; Bennett J; Dubois C; Sinnaeve P; Wiyono S; Coosemans M; Belmans A; D'hooge J; Vrolix M; Desmet W
EuroIntervention; 2014 Aug; 10(4):439-48. PubMed ID: 25138182
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
Kitabata H; Loh JP; Pendyala LK; Badr S; Dvir D; Barbash IM; Minha S; Torguson R; Chen F; Satler LF; Suddath WO; Kent KM; Pichard AD; Waksman R
Am J Cardiol; 2013 Oct; 112(8):1093-8. PubMed ID: 23827397
[TBL] [Abstract][Full Text] [Related]
19. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study.
Radu MD; Räber L; Kalesan B; Muramatsu T; Kelbæk H; Heo J; Jørgensen E; Helqvist S; Farooq V; Brugaletta S; Garcia-Garcia HM; Jüni P; Saunamäki K; Windecker S; Serruys PW
Eur Heart J; 2014 Mar; 35(12):795-807. PubMed ID: 24132187
[TBL] [Abstract][Full Text] [Related]
20. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
